Fasoracetam: The Racetam Built for ADHD and Anxiety the FDA Forgot About

Fasoracetam dosage doesn’t come from bro-science guesswork. It comes from 2 real trial programs, run decades apart, in 2 completely different populations, at 2 different dose ranges. The first, run by Nippon Shinyaku in Japan through the 1990s, pushed fasoracetam through phase 3 in elderly vascular-dementia patients and it failed to beat placebo. The second, run 20 years later at Children’s Hospital of Philadelphia, tested it in adolescents 12 to 17 with a specific glutamate-receptor gene signature, titrating up to 400 mg twice daily over 4 to 5 weeks, and it moved ADHD severity scores with real statistical weight. Neither trial ran in healthy adults. That gap is the honest starting point for anyone asking what dose to take, because the number on a gray-market vendor’s label wasn’t derived from either study.

What fasoracetam is

Fasoracetam, also known by its development codes NS-105 and NFC-1, came out of Nippon Shinyaku’s racetam research program in the 1990s. It shares the racetam backbone with piracetam and aniracetam, but the receptor target is different. Piracetam works mostly through cholinergic signaling. Fasoracetam works mostly through metabotropic glutamate receptors and the GABA-B system, which is why the subjective reports lean anxiolytic rather than stimulant.

The mechanism: 2 systems in a balancing act

Metabotropic glutamate receptors set the background tone of glutamate signaling. Ionotropic receptors handle the fast, moment-to-moment firing instead. Animal pharmacology work found fasoracetam activates group I mGluRs, which stimulates adenylate cyclase, while it also activates group II and III mGluRs, which inhibits that same enzyme. That push and pull is the proposed mechanism behind a compound that calms intrusive thought without sedating.

The GABA-B side adds a second lever. A rat study found repeated fasoracetam dosing increased the number of GABA-B receptors in the cerebral cortex, without changing beta-adrenoceptor or serotonin-2 receptor binding, and that same increase tracked with reduced learned helplessness in a forced-swim and shuttle-box model. That’s an animal finding; nobody has confirmed the same receptor shift happens in people. It’s still the basis for the cycling logic below: if the mechanism runs through receptor upregulation rather than simple occupancy, running it every day without a break would blunt the exact effect a user is chasing.

What the trials showed

Start with the failure, because it’s instructive. Nippon Shinyaku spent north of $200M taking fasoracetam through phase 3 for vascular dementia. Multiple randomized, placebo-controlled studies measured cognitive outcomes on the standard Alzheimer’s-disease cognitive subscale, and the drug never separated from placebo by enough to satisfy a regulator. Development stopped. That’s evidence the molecule did nothing detectable for vascular dementia in elderly patients on that particular scale. It’s a narrow finding about 1 population and 1 endpoint.

The molecule surfaced again 2 decades later in a completely different population. Researchers at Children’s Hospital of Philadelphia screened over 200 ADHD patients for disruptive variants in glutamate-receptor network genes and enrolled 30 adolescents, ages 12 to 17, who carried them. The open-label, placebo-controlled phase 1b trial ran single-dose pharmacokinetic testing from 50 to 800 mg, then symptom-driven dose advancement up to 400 mg twice daily for 4 weeks. Clinical severity and improvement scores both moved with real statistical weight by week 5.

The follow-up randomized, double-blind phase 2 trial in the same population missed its primary endpoint on the standard ADHD rating scale against placebo. It did clear a pre-specified secondary bar: a meaningful share of patients hit a 30% or greater symptom reduction, significantly more often than on placebo. That’s a mixed result, and it’s still the most rigorous human data the molecule has.

Outside those 2 programs, healthy adult dosing data is close to nonexistent. Everything past this point, including what circulates in fasoracetam reddit threads about daily dosing, gets extrapolated from a pediatric ADHD trial and a failed elderly-dementia program. Neither one ran on people using it the way most buyers actually use it.

The tolerance and cycling logic

If GABA-B upregulation really is the mechanism, continuous dosing works against itself: the receptor count climbs, the same dose produces less effect, and pushing the dose up to compensate moves toward genuine GABA-B agonism, which is where sedation and dependence risk actually live. The adolescent trials didn’t run long enough to test this directly. The cycling protocols that circulate online, weeks on followed by weeks off, are a reasonable inference from the animal mechanism. Treat that inference as an educated guess, because that’s what it is; no human trial has tested a cycling schedule against continuous dosing.

Harms and unknowns, stated first

What isn’t known matters more here than what is. There’s no published human data past a few weeks of use. There’s no adult healthy-volunteer safety trial. There’s no data on interactions with SSRIs, benzodiazepines, or other GABA-ergic compounds, and stacking fasoracetam with something like phenibut doubles up on the same receptor system with no trial ever checking what that combination does. Sourcing sits entirely in the unregulated gray market, so product purity depends on which vendor a buyer trusts.

What is known: the adolescent trials reported a benign safety profile over 4 to 5 weeks, with headache and mild fatigue as the main complaints, both consistent with the cholinergic and GABA-B mechanisms rather than anything alarming. No sexual side effects, no withdrawal pattern, and no dependence signal showed up in that window. A 4-week trial in teenagers under medical supervision differs from an adult self-dosing off a gray-market capsule for months in 3 ways at once: different population, different duration, different oversight.

What I’ve felt running it

I’ve run fasoracetam in cycles, watching for the same thing the trials measured: fewer racing, intrusive thoughts and easier task initiation, without the wired feeling stimulants give me. It builds slowly, over a week or more, not in an afternoon the way piracetam can. I can’t hand you a clean before-and-after number here, because no home test isolates fasoracetam’s effect from sleep, training load, and everything else running at the same time. What I can tell you is that the pattern I notice lines up with what the receptor mechanism predicts, which is about as far as self-experimentation can honestly take a claim.

Fasoracetam vs. noopept vs. coluracetam

Fasoracetam has the most rigorous published human trial behind it of the 3. That trial ran in ADHD-diagnosed adolescents; the healthy adults buying it off research-chemical sites are a different population entirely.

Sourcing and the gray market

There’s no regulator checking any of this. Buy the monohydrate form for stability, and don’t buy from a vendor that won’t hand over a current third-party certificate of analysis. Given what the turkesterone market’s own testing scandals showed about mislabeled ecdysteroid products, treat any unregulated compound the same way: verify before you dose, not after.

Bottom line

The fasoracetam dosage question has a real trial answer, and it’s a pediatric ADHD protocol, up to 400 mg twice daily, run under medical supervision for 4 to 5 weeks. It isn’t a healthy-adult self-directed protocol, because that trial has never been run. The mechanism is well mapped in animals: mGluR rebalancing plus GABA-B upregulation. The human record is 1 failed elderly-dementia program and 1 mixed-result adolescent ADHD program, with almost nothing in between. Anyone running this compound as an adult is extrapolating from both, same as I am.

Frequently Asked Questions

What is the right fasoracetam dosage?

The only dose-ranging human data comes from a pediatric ADHD trial that advanced up to 400 mg twice daily over 4 weeks under medical supervision. No healthy-adult dosing trial exists, so adult protocols circulating online are extrapolated, not trial-derived.

Is fasoracetam better than noopept?

They aren’t interchangeable. Fasoracetam is non-stimulant and anxiolytic, building over a week or more through mGluR and GABA-B modulation. Noopept acts within an hour through a different mechanism tied to BDNF and NGF signaling. Which is “better” depends on whether the goal is calming intrusive thought or a faster cognitive lift.

Why did fasoracetam fail its dementia trials but pass its ADHD trials?

The dementia program tested elderly patients on a general cognitive scale and never separated from placebo. The ADHD program pre-selected adolescents carrying specific glutamate-receptor gene variants, a genetically defined subgroup the original dementia trials never screened for.

Is fasoracetam legal?

It’s not FDA-approved for any indication in the US and exists in a gray market, sold through research-chemical vendors rather than as a regulated supplement or prescription drug.

What are the side effects of fasoracetam?

The published adolescent trials reported headache and mild fatigue as the main complaints over 4 to 5 weeks, with no sexual side effects, withdrawal pattern, or dependence signal in that window. Long-term adult safety data doesn’t exist.